65,437 trials
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Phase I: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Bortezomib, Lenalidomide and Dexamethasone — 10 mg/kg (Phase II dosing for elotuzumab)
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Study Treatment — 98.1; 100…
Opioid Use
Primary: Prescribed Post-discharge Opioids — 55.3; 62.8 Oral Morphine Equivalent units (OME)
Postoperative Pain
Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48). — 386.12; 391.56; 405.82…
Idiopathic Intracranial Hypertension
Primary: Intracranial Pressure — -0.3; -4.3 cmCSF
Relapsed and/or Refractory Multiple Myeloma
Primary: Progression Free Survival (PFS) — 4.8; 7.1 months — p==0.477
Parkinson Disease
Primary: Mean Change From Baseline Freezing of Gait (FOG) After First 12 Weeks of Treatment, as Measured by the Giladi Freezing of Gait Questionnaire (FOG-Q). — 13.75; 14.57…
Generalized Myasthenia Gravis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability — 11; 12; 9; 12 Participants
Concussion
Primary: Neurobehavioral Symptom Inventory — 33; 33 score on a scale
Chronic Pain
Primary: Activity Participation — 156.0; 135.8 score on a scale — p==0.90
Peanut Allergy
Primary: Percentage of Treatment Responders at Month 12; Analyzed in Overall Population — 45.3; 41.1; 50.0; 25.0 percentage of participants — p=0.0292
Alcohol Use Disorder
Primary: Recruitment Feasibility (Time, in Months,) Required to Recruit, Screen and Conduct the Study Procedures — 7.0 months
Hemophilia A · Severe Hemophilia A
Primary: Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627 — 0 percentage of paticipants
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Postoperative Pain
Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With…